NCT02426892View on ClinicalTrials.gov

Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Solid Tumors
Interventions
BIOLOGICAL

ISA 101

100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.

DRUG

Nivolumab

3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

ISA Pharmaceuticals B.V.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER